SCHEMBL30769925

SCHEMBL30769925

CO[C@H]1CC[C@@H](c2nc3c(C4CCN(C(=O)OC(C)(C)C)CC4)ccnc3[nH]2)CC1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 4/20 0.47
▸ HPGDS O60760 1/20 0.44
▸ PDE10A Q9Y233 1/20 0.43
▸ DDB1 Q16531 2/20 0.42
▸ CRBN Q96SW2 2/20 0.42
▸ JAK2 O60674 2/20 0.42
▸ JAK3 P52333 2/20 0.42
▸ JAK1 P23458 1/20 0.42
▸ TYK2 P29597 1/20 0.42
▸ PARP1 P09874 3/20 0.42
▸ CCNT1 O60563 2/20 0.40
▸ CDK9 P50750 2/20 0.40
▸ CCNK O75909 1/20 0.40
▸ CDK12 Q9NYV4 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ THRB P10828 1/20 0.40
▸ PTK2 Q05397 1/20 0.40
▸ HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27059728 1.00 GPR119 (0.47) GPR119HPGDSPDE10ADDB1CRBN
SCHEMBL30769828 1.00 GPR119 (0.47) GPR119HPGDSPDE10ADDB1CRBN
SCHEMBL27059727 1.00 GPR119 (0.47) GPR119HPGDSPDE10ADDB1CRBN
SCHEMBL27035226 1.00 GPR119 (0.47) GPR119HPGDSPDE10ADDB1CRBN
SCHEMBL24683439 0.94 HPGDS (0.48) GPR119HPGDSPDE10ADDB1CRBN
SCHEMBL27059725 0.90 HPGDS (0.46) GPR119HPGDSPDE10ADDB1CRBN
SCHEMBL27035302 0.90 HPGDS (0.46) GPR119HPGDSPDE10ADDB1CRBN
SCHEMBL27035383 0.88 HPGDS (0.45) GPR119HPGDSPDE10ADDB1CRBN
SCHEMBL27035497 0.88 PARP1 (0.45) PARP1MAPTHTT
SCHEMBL30769878 0.86 CCNT1 (0.46) GPR119HPGDSPDE10ADDB1CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260022116-A1 IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF SANOFI-AVENTIS RECHERCHE & DÉVELOPPEMENT (FR) 2026-01-22 — — US disclosed
EP-4558500-A1 IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF Sanofi (FR) 2025-05-28 — — EP disclosed
WO-2024017977-A1 IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF SANOFI (FR) 2024-01-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260022116-A1 IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF MAPK1, MAPK3, MAPK6 GPR119 1614/4885HPGDS 2107/4885PDE10A 2269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback